Protective effect of nicotinamide and \(\text{l}\)-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence

Katarzyna Sztormowska-Achranowicz\(^1\) · Zbigniew Jankowski\(^2\) · Ivan Kocić\(^1\)

Received: 10 February 2020 / Revised: 27 June 2020 / Accepted: 29 June 2020 / Published online: 6 July 2020
© The Author(s) 2020

Abstract

Background The purpose of this paper was to examine the effects of nicotinamide (ND) and \(\text{l}\)-arginine (\(\text{l}\)-ARG) on pulmonary vascular and heart changes induced by pulmonary hypertension in rats in a gender-dependent way.

Methods Experiments were performed on male (M) and female (F) rats. PAH was induced via monocrotaline injection (sc, 60/kg B.W.) on day one of the 23-day observational period. After that, the animals were sacrificed, hearts removed and weighed and the papillary muscles isolated to measure force of contraction \((F_c)\). Morphological changes of pulmonary vessels were also examined.

Results Mixed diet supplementation with \(\text{l}\)-ARG + ND prevented highly significant right ventricle enlargement induced by PAH in both, male and female rats. Weight ratios between the right ventricle (RV) on one side and the left ventricle with septum on the other \((\text{LV} + \text{S})\) decreased from 0.46 ± 0.016 g to 0.29 ± 0.006 g in males and from 0.63 ± 0.03 g to 0.24 ± 0.008 g in females, \(n=6\), \(p<0.001\). Additionally, PAH increased basal contractility in female groups, and each of the diet allocations \((\text{l}\)-ARG, ND, and mixed) were found to restore contractility to control values. All diet protocols in male and female restored decreased responsiveness of the myocardium to norepinephrine in hearts obtained from rats with PAH and prevented vascular changes observed in pulmonary hypertension (thickness of blood vessels and cell infiltration).

Conclusion Our study suggests that \(\text{l}\)-arginine, nicotinamide or both play a positive role in right ventricle function or the process reducing pulmonary vascular remodeling especially in a gender-independent way.

Keywords Gender · Monocrotaline · Nicotinamide · \(\text{l}\)-Arginine · Pulmonary arterial hypertension · Heart contractility

Introduction

Pulmonary arterial hypertension (PAH) is a clinical condition caused by a multitude of factors, and affects the functioning of the myocardium and pulmonary circulation [1]. Progression of this disease leads to the narrowing of pulmonary arteries, elevation of pulmonary resistance (PVR), right ventricle remodeling (cardiomyocyte necrosis) and reduction of right ventricular ejection fraction [2]. Finally, it results in acute or chronic heart failure and the death of the patient [3]. According to the literature, PAH is defined as an elevated mean pulmonary artery pressure > 25 mmHg at rest and > 30 mmHg during exercise and increased pulmonary vascular resistance [4]. Interestingly, the pressure in the right atrium and cardiac output (CO) are one of the most important indicators predicting the survival rate of PAH patients. Currently, therapeutic recommendations for PAH are focused on the pulmonary vessels and do not consider simultaneous treatment of myocardium dysfunction [5]. In this context, the use of sex hormones, especially progesterone, nicotinamide and \(\text{l}\)-arginine is promising [6–8]. Nicotinamide is known to have many biological and therapeutic properties, including antioxidant, anti-inflammatory, and proapoptotic [7]. Studies suggest nicotinamide has a protective effect on acute lung damage caused by ischemia, endotoxin or oxidative stress [8]. Recently, studies have shown that nicotinamide can inhibit poly (ADP-ribose) polymerase (PARP), which in response to free radicals increases...
rapidly, causing a decrease in NAD+ and ATP (metabolic homeostasis). The role of nicotinamide in PARP inhibition is important in vascular smooth muscle cells (inhibits spasm), in myocardial cells or cancer cells as it maintains an appropriate level of ATP [9]. In addition, nicotinamide has been shown to regulate myocardial SUR2A receptors by increasing cardiac resistance to an ischemia/reperfusion reaction [10].

L-Arginine is a nitric oxide (NO) donor. Some diseases, for example atherosclerosis, hypercholesterolemia or pulmonary hypertension significantly reduce the level of NO [11, 12]. Vascular endothelial cells use L-arginine as a NO precursor for physiological processes such as: inhibition of myocyte proliferation, vascular remodeling, reduction of vascular wall tension, inhibition of leukocyte aggregation and platelet aggregation. In addition, NO activates the Ca2+/calmodulin complex, which has a cardioprotective and smooth muscle relaxant effect [13]. It can reduce the level of free radicals and minimize inflammation in the blood vessels. In the heart, it reduces pulmonary resistance [14], maintains a low right heart ventricle index, increases myocardial contractility, reduces reactions to oxidative stress, and increases myocyte relaxation [15]. Therefore, this study was designed to investigate whether the addition of ND and L-ARG to the standard diet, separately and in combination, would have an impact on changes to heart contractility and pulmonary vessel structure induced by pulmonary hypertension. The study design was based on a well-established model of pulmonary hypertension in male and female rats.

Materials and methods

Animals and experimental design

The protocol of our experimental study was approved by the Local Ethics Committee for Animal Experiments No 3, Medical University of Gdansk. All experimental procedures were performed on male and female Wistar albino rats with an initial body weight of 198 ± 3 g. The animals were maintained under a controlled temperature of 23 ± 2 °C, a relative humidity of 53 ± 2% and a fixed lighting cycle of 12 h light/night for 7 days before the start of experiment. The animals were divided into two per cage and separated by gender. The animals received AIN93G food (ssniff® Spezialdiäten GmbH, Soest, Germany) and water ad libitum throughout the entire study. Male (M) and female (F) rats were divided into 16 groups of 6 animals each, as follows:

- Control groups that received a standard diet: group-1 (male control-MC); group-2 (female control-FC); observational period 1–23 days;
- Groups that received L-arginine in their drinking water (2.5% solution/po from the 7th day): group-3 (male + L-ARG = MARG) and group-4 (female + L-ARG = FARG);
- Groups that received a nicotinamide-rich, diet (500 mg/kg of food/po from the 7th day): group-5 (male + ND = MND) and group-6 (female + ND = FND);
- Groups that received both L-ARG and ND at the same time: group-7 (MARG + ND) and group-8 (FARG + ND);
- Groups with pulmonary arterial hypertension (PAH) induced by monocrotaline 60 mg/kg B.W./sc, applied on the 1st experiment day): group-9 (MPAH) and group-10 (FPAH);
- Groups with PAH that received L-ARG from the 7th day: group-11 (MPAH + ARG) and group-12 (FPAH + ARG);
- Groups with PAH that received ND from the 7th day: group-13 (MPAH + ND) and group-14 (FPAH + ND);
- Groups with PAH that received both L-ARG and ND at the same time: group-15 (MPAH + ARG + ND) and group-16 (FPAH + ARG + ND).

All control groups (1–8) were given an equal volume of 0.9% sodium chloride solution (1 ml/kg B.W./sc) on the 1st day of the 23-day observational period, instead of monocrotaline (MCT) which was applied to experimental groups (9–16). MCT was dissolved in 1N HCl, and adjusted to a pH 7.4 with 1N NaOH. The diet regimen rich in L-arginine was four times the recommended dose for a rat [16]. The diet regimen rich in nicotinamide was 17 times higher than the recommended dose [17], however it did not exceed the maximal dose permitted in rats. The animals were weighed once a week. The entire experimental procedure is shown in Fig. 1.

After 23 days, the animals were sacrificed via overdose with sodium pentobarbital (60 mg/kg ip), blood samples were collected, the chest opened and the heart and lungs removed. The blood samples (1 ml from femoral arteries) were then centrifuged (3000 rpm) with citrate (v/v 9:1) for 15 min. The obtained plasma was stored at − 80 °C for further biochemical analysis. The heart was quickly removed and placed in a preparation dish with Krebs–Henseleit modified solution (KHS) and aerated with carbogen. To remove the thrombocytes and safely stop the contraction of the heart, the solution was cooled to 12 °C. Then, as quickly as possible, a papillary muscle > 3 mm long and < 1 mm in diameter from the right ventricle was isolated. The papillary muscle was placed in an organ bath. The lungs were placed in 8% of buffered formalin for later histopathological and morphometric analysis.

Measurement of plasma level of nicotinamide

To detect the level of ND in plasma we used high-performance liquid chromatography with mass detection (LC/MS)
in accordance with the previously developed method [18]. Blood samples for this analysis were collected on the 23rd day of the observational period in groups: 1, 2; 5, 6; 9, 10; 13, 14. The level of l-arginine in plasma was not able to be determined, as the compound is metabolized rapidly and the dose we used for supplementation had been proven to be effective [19].

Measurement of organ mass

To rate the degree of right ventricle size changes in different experimental groups, the hearts were divided into two sections: the right ventricle (RV), and the left ventricle with the septum (LV + S), and each section was weighed separately (Fulton index) [20–23]. The normal ratio RV against LV + S was 0.2. A result above 0.3 was considered as being classified PAH [24]. Additionally, the weight of individual heart chambers to the final body weight (FBW) were evaluated for: the right ventricle (RV/FBW), the left ventricle with the septum (LV + S/FBW), and for the total weight of the heart to final body weight (HW/FBW).

Measurement of force of contraction

Papillary muscle was excised from the right ventricle and placed into an organ bath of 2 ml (Steiert organ bath, type 813, DC temperature regulator, type 319, Hugo Sachs Elektronik, Germany). The tissue was perfused with KH solution with the following composition: NaCl 120.4; KCl 4.9; MgCl₂×6H₂O 0.6; CaCl₂ 2.5; NaH₂PO₄×H₂O 1.0; NaHCO₃ 15.3; glucose 11.5; sodium pyruvate 2.0. Constant rate of perfusion was approximately 8 ml/min and was maintained by means of a peristaltic pump (peristaltic pump, type 371, Unipan, Poland). Constant solution temperature was 37 °C ± 0.5. The solution was aerated with a gas mixture of 95% O₂ and 5% CO₂, the pH was kept constant at 7.4. The tissue was incubated for 60 min at 4 mN ± 0.12 of resting force (1 mN = 0.1 g), in contact with two silver electrodes for stimulation at 1 Hz, square wave current, 3 ms pulse duration, 2000 ms base cycle length, 20% amplitude above the threshold voltage, generated by the pacemaker with the insulating unit (ST-02, Experimetria, Hungary). Fc was measured with an isometric transducer (F-30, HSE, Germany) and a differential with measuring bridge type 336 (HSE, Germany). The results were recorded using a two-channel line recorder (Model 202, Cole-Parmer, United States). After 60 min stabilization, the papillary muscle was treated with noradrenaline in increasing, sequential concentrations from 0.1 to 100 μM.

Histopathology and morphometric measurement of pulmonary arteries

The lungs obtained from the rats were preserved in 8%buffered formalin for histopathological and morphometric analysis. The tissues were stained with hematoxylin and eosin (H&E) to identify any structural changes. The preparations were examined under a light microscope (Carl Zeiss, type JenaMed, Germany) at 400× magnification. Quantitative analysis included 15 fields of cross-sectional view of each case. Structural changes were interpreted and classified using a scale ranging from + (presence of damage) to +++ (very serious and extensive damage). A score of 0/+ indicated that in a given case, there was no (“0”) to some damage (“+”) observed. A single “0” sign indicated the normal appearance of tissue. Morphometric analysis was carried out at 400× magnification using a set containing a light microscope, a digital camera (Olympus, type DP21,
Japan) and a computer with software (cell® Sens Standard 1.7, Olympus, Japan). Two types of pulmonary arteries were selected for analysis: distal arterioles in the vicinity of the alveoli (vascular diameter from 30 to 100 μm) and arteries at the bronchioles (vascular diameter from 100 to 200 μm). We measured wall thickness of the selected artery from the inner lumen of the vessel to the outer wall of the vessel, in the thickest and thinnest part of the vessel (20 measurements in each case).

**Chemicals and diet**

L-arginine, monocrotaline and noradrenaline were purchased from Sigma-Aldrich, St. Louis, MO, USA. Nicotinamide (nicotinamide-rich diet) was sourced from ssniff® Sapsulation GmbH, Soest, Germany.

**Statistical analysis**

The force of contraction ($F_c$) was expressed in mN (1 g = 10 mN). Morphometric measurement was expressed in μm. Each experiment result was evaluated as mean ± standard error (SEM) and statistical analysis was performed using STATISTICA version 13.3 (StatSoft®, Inc. 2017, https://www.statsoft.com). The multi-way ANOVA was applied to compare and evaluate data from more than two independent groups along with the multiple comparison Neuman–Keuls test, where deemed necessary. A difference of $p < 0.05$ was considered statistically significant.

**Results**

**The serum levels of nicotinamide metabolites**

We determined the plasma concentrations of four ND metabolites. It was observed that gender significantly differentiates the metabolite value of Met-2PY ($F_{1,12} = 15.40, p = 0.002$) and the type of diet administered significantly affects the value of Met-2PY ($F_{3,12} = 28.88, p = 0.000009$), and a significant interaction between gender×diet ($F_{3,12} = 6, p = 0.006$). Post hoc comparisons showed that the level of Met-2PY in male serum was higher ($p = 0.0003$) compared to the female group. Also, Met-4PY levels was significantly differentiates through gender ($F_{1,12} = 13.82, p = 0.002$) and the type of diet was administrated significantly affects the value of Met4PY ($F_{3,12} = 11.2, p = 0.0008$), but no interaction was showed between gender×diet. Post hoc comparisons showed that the level of Met-4PY in male was higher ($p = 0.0006$) compared to the female group and only diets significantly differentiated Met-NA levels ($F_{3,12} = 19.76, p = 0.00006$). Others data were shown in Table 1.

Table 2 showed that pulmonary hypertension reduced the FBW in 18% of all male groups, regardless of the type of diet provided. Interestingly, the FBW reduction induced by pulmonary hypertension in female rats was smaller than that observed in male groups, with an average decrease of approximately 7%. Multivariate analysis of variance has shown a significant effect of gender ($F_{1,80} = 2354.1, p = 0.0001$), administered diets ($F_{7,80} = 51.2, p = 0.0001$) and a significant interaction between gender×diets ($F_{7,80} = 22.9, p = 0.0001$) on FBW. Post hoc test showed that FBW in male ($p = 0.0001$) was higher than in female. The multi-way ANOVA revealed that gender ($F_{1,80} = 46.19, p = 0.00001$) and administrated diets ($F_{7,80} = 7.84, p = 0.00001$) significantly differentiates HW/FBW and additionally has shown a significant interaction between gender×diets ($F_{7,80} = 2.17, p = 0.04$). Post hoc test showed that HW/FBW in male ($p = 0.0001$) was higher than in female. The analysis showed that gender ($F_{1,80} = 115.8, p = 0.00001$) and type of diet ($F_{7,80} = 24.2, p = 0.00001$) significantly differentiate the RV value and

**Table 1** Effects of nicotinamide-rich diet on serum level of metabolites nicotinamide in pulmonary arterial hypertension male and female rats induced by monocrotaline

| Groups | Met-NA  | Met-2PY  | Met-4PY  | 4-PYR  |
|--------|---------|----------|----------|--------|
|        | ($♂$) Male | ($♀$) Female | ($♂$) Male | ($♀$) Female | ($♂$) Male | ($♀$) Female | ($♂$) Male | ($♀$) Female |
| μmol/L |          |          |          |        |
| Control | 29.13 ± 10.59<sup>a</sup> | 23.6 ± 4.49<sup>a,b</sup> | 0.26 ± 0.12<sup>a</sup> | 0.58 ± 0.11<sup>b</sup> | 3.14 ± 0.61<sup>b,f</sup> | 1.62 ± 0.041 | 1.68 ± 0.87 | 1.04 ± 0.33 |
| ND     | 570.85 ± 78.63 | 476.07 ± 66.13 | 13.29 ± 1.61 | 7.21 ± 1.7 | 7.68 ± 0.85 | 4.53 ± 1.22 | 1.1 ± 0.32 | 1.02 ± 0.18 |
| PAH    | 12.945 ± 0.22<sup>a,k</sup> | 17.64 ± 2.78<sup>b</sup> | 0.31 ± 0.14<sup>b,k</sup> | 0.19 ± 0.01 | 2.42 ± 0.027<sup>d</sup> | 1.665 ± 0.35 | 0.95 ± 0.09 | 1.23 ± 0.28 |
| PAH + ND | 599.59 ± 168.03 | 363.42 ± 41.66 | 15.72 ± 2.69 | 4.8 ± 0.37 | 7.55 ± 1.24 | 3.64 ± 0.91 | 1.92 ± 0.67 | 1.14 ± 0.2 |

Met-NA -N-methyl nicotinamide, Met-2PY -N-methyl-2-pyridone-5-carboxamide, Met-4PY -N-methyl-4-pyridone-3-carboxamide, 4-PYR -4-pyridone-3-carboxamide-1-β-D-ribofuranoside. Each value represents the mean±SEM, $n = 2–3$ rat per groups. Statistically significant differences was indicated by the symbols: <sup>a</sup>$p = 0.01$, <sup>b</sup>$p = 0.02$, <sup>c</sup>$p = 0.004$, <sup>d</sup>$p = 0.0005$, <sup>e</sup>$p = 0.0007$ vs. ND male or female group; <sup>f</sup>$p = 0.01$, <sup>g</sup>$p = 0.04$, <sup>h</sup>$p = 0.004$, <sup>i</sup>$p = 0.008$, <sup>j</sup>$p = 0.0002$, <sup>k</sup>$p = 0.0003$ vs. PAH + ND male or female group.
the occurrence of interaction ($F_{1,80} = 3.3$, $p = 0.003$), which means that the influence of gender depends on the type of diet used. The post hoc test showed that RV in males was significantly higher ($p = 0.0001$) than in females. In addition, it was shown that in PAH both in males and females there is a significant increase in RV value compared to the groups receiving diets in PAH. The multi-way ANOVA revealed that gender does not differ the increase in RV/LV+S in females. The use of different diets significantly affects RV/LV+S ($F_{1,80} = 5.87, p = 0.00002$). The post hoc test showed the significant increase in RV/LV+S in PAH groups in males and females, and decrease of this parameter after the diet in PAH. The multi-way ANOVA revealed a significant impact of gender ($F_{1,80} = 8.14$, $p = 0.005$) and type of treatment ($F_{1,80} = 31.53$, $p = 0.00001$) and their interaction ($F_{1,80} = 2.4$, $p = 0.02$) on RV/FBW. The post hoc test showed that the RV/FBW value is higher in males ($p = 0.005$) than in females. The multi-way ANOVA revealed a significant effect of gender ($F_{1,80} = 505.71$, $p = 0.00001$) and effect of diet type ($F_{7,80} = 11.46$, $p = 0.00001$) on LV+S. However, there is no interaction between them. The post hoc test showed that the LV+S value is definitely higher in males ($p = 0.0001$) than in females. It was also shown that gender ($F_{1,80} = 57.16$, $p = 0.00001$) and the type of diet ($F_{7,80} = 7.76$, $p = 0.00001$) used significantly differentiated the LV+S/FBW value and showed interactions between them ($F_{7,80} = 7.80$, $p = 0.01$). Post hoc test showed a higher value in males ($p = 0.0001$) than in females for this parameter (Table 2).

The effects of noradrenaline on the force of contraction ($F_c$)

First, we compared the resting force (or basal contractility induced by electrical stimuli, see “Materials and methods”) of isolated papillary muscle from different experimental conditions.
groups (Fig. 2). The multi-way ANOVA revealed a significant difference in the impact of gender ($F_{1,30} = 5.62$, $p = 0.02$) and the type of diet ($F_{7,30} = 4.3$, $p = 0.0004$) used and their interaction ($F_{7,30} = 2.14$, $p = 0.04$) on resting force. We found that the addition of diets and pulmonary arterial hypertension had an effect on resting force causing a significant reduction in basal contractility compared to PAH. Post hoc comparisons showed that males have higher $F_c$ ($p = 0.02$) than females. There were significant differences of the force of contraction in females from the Control group ($p = 0.01$ and $p = 0.01$) and PAH ($p = 0.007$ and $p = 0.008$) compared to the ND group and ARG + ND, respectively. Administration of ND ($p = 0.01$) and ARG + ND ($p = 0.039$) in pulmonary hypertension significantly reduced $F_c$ compared to PAH only in female rats. The next step was to examine the effect of pharmacological stimulation on contraction strength. We used noradrenaline as a potent stimulator of $\alpha$ and $\beta_1$ adrenoceptors, strongly expressed in the hearts of rats. The multi-way ANOVA revealed that the type of diet administered ($F_{2,560} = 27.14$, $p = 0.00001$) significantly differentiated the effect of noradrenaline on the force of contraction of the heart muscle and significant gender-diet interactions ($F_{7,560} = 2.88$, $p = 0.005$) were demonstrated. The addition of ND and l-ARG, separately and in combination, decreased the reaction of papillary muscle to noradrenaline in control groups or in groups with PAH. However, the reduction of noradrenaline effects by ND and l-ARG was much stronger in groups with PAH (Figs. 3, 4).

The effects of nicotinamide and l-arginine on pulmonary vascular remodeling induced by PAH in male and female rats

Table 3 presents data related to the morphologic changes in pulmonary vessels induced by PAH in male and female rats in both the absence and presence of l-arginine and nicotinamide. As Figs. 5 and 6 show, PAH induced necrotic lesions, perivascular edema, interstitial pneumonia, atelectasis, platelets plug, and endovascular infiltrations with macrophages, which were observed in both, males and females. It is important to note that the small changes identified in pulmonary arterioles (diameter up to 0.3 mm) are progressive occlusions, observed in more than 90% of cases. Additionally, in more than 80% of females with PAH, pulmonary edema was observed, however with a smaller overgrowth of the medial vascular layer when compared to males with PAH. The addition of l-ARG reduced the aforementioned changes (in males in over 70% of cases, and in females in over 60% of cases). On the other hand, aside from the reduction of some morphological changes induced by pulmonary hypertension, the addition of ND induced intravascular inflammation (10% of males, 60% of females), as well as infiltration with macrophages and angioedema (10% of males and 40% of females). Finally, a combined l-ARG + ND diet decreased the level of changes appearing in PAH in more than 70% of the studied cases and also reduced the abnormalities associated with the administration of nicotinamide alone, in both males and females. The multi-way ANOVA showed that the type of diet administered significantly differentiates the pulmonary arterioles among the follicles in the thickest ($F_{7,59} = 39.06$, $p = 0.00001$) and in the thinnest ($F_{7,59} = 39.06$, $p = 0.00001$) place. Gender does not significantly affect arterial thickness. There was also no interaction of gender x diet type. In contrast, multi-way ANOVA showed that the type of diet administered significantly differentiates the pulmonary arterioles among the bronchioles in the thickest place ($F_{7,58} = 79.59$, $p = 0.000001$) and significant interaction between gender and diet type ($F_{7,58} = 4.007$, $p = 0.001$) was demonstrated.

![Fig. 2](image-url) The effect of nicotinamide-rich diet, l-arginine diet and pulmonary arterial hypertension (PAH) on the resting force of contraction ($F_r$) of isolated right papillary muscles from male and female rats. Each value represents the mean ± SEM of six animals from each experimental groups. Statistically significant differences are indicated by the symbols: $\dagger p = 0.01$, $\ddagger p = 0.007$ vs. ND; $\ddagger p = 0.01$, $\ddagger\ddagger p = 0.008$ vs. ARG + ND; $\ddagger p = 0.01$, $\ddagger\ddagger p = 0.039$ vs. PAH
The multi-way ANOVA revealed that gender ($F_{1.58} = 8.84$, $p = 0.004$) and diet type ($F_{7.58} = 117.81$, $p = 0.00001$) significantly differentiate arterioles among the bronchioles in the thinnest place. A significant interaction of gender x diet type ($F_{7.58} = 4.91$, $p = 0.0002$) has also been shown. Post hoc test comparisons showed that females had a smaller increase in arterial wall thickness at the thinnest place than males. It should be noted that PAH significantly increased the thickness of small pulmonary arteries located around the alveoli and bronchi, and the addition of l-ARG and ND, separately and jointly, reduced this wall thickness in approximately 50% of cases (Figs. 7, 8).

Fig. 3 The effects of noradrenaline on the force of contraction of isolated papillary muscles from male rats fed with a nicotinamide-rich diet and l-arginine in control groups and groups with PAH. Each value represents the mean ± SEM of six animals from each experimental groups. Statistically significant differences are indicated by the symbols: *$p = 0.036$, $b$ $p = 0.039$ vs. MPAH.

Fig. 4 The effects of noradrenaline on the force of contraction of isolated papillary muscles from female rats fed with a nicotinamide-rich diet and l-arginine in control groups and groups with PAH. Each value represents the mean ± SEM of six animals from each experimental groups. Statistically significant differences are indicated by the symbols: *$p = 0.03$ vs. FPAH.
Given that pulmonary arterial hypertension (PAH) is an extremely complex disease with a poor prognosis [25], further investigation in this clinical field is essential. This study is the first to investigate the impact of oral administration of l-arginine (l-ARG) and nicotinamide (ND), separately and in combination, on myocardial function and histopathological changes in pulmonary arteries during the development of PAH in a gender-dependent way. The major novel finding of this study is that the combination of the oral supplements l-ARG and ND prevented right ventricle enlargement and vascular changes in small pulmonary arteries induced by pulmonary hypertension, especially in females. Additionally, the contractility of the right ventricle and the reaction to a catecholamine (noradrenaline) was preserved and restored to the normal, control level.

We used a well-established model of PAH induced by monocrotaline (MCT) in rats [26]. MCT is a macrocyclic pyrrolizidine alkaloid obtained from seeds of a Crotalaria spectabilis plant. The exact mechanism of action of this compound is not known. After administration of MCT, a “monocrotaline syndrome” appears which is manifested by: acute necrotic inflammation of the pulmonary arteries and hypertrophy of the right ventricle [27]. In this study, MCT was administered at a dose of 60 mg/kg B.W., with an observational period of 23 days to allow full development of pathological changes in heart and pulmonary circulation. Higher doses may contribute to hepato-, cardio-, and nephrotoxicity and are associated with a higher mortality rate [27]. The use of this model was confirmed to be effective by Meyrick et al., who observed the remodeling of distal pulmonary arteries after 3 days and RV hypertrophy 7–14 days after MCT was administered [28]. Additionally, significant reductions of the FBW (especially in male rats) [29], increased levels of catecholamines and the enlargement of the right ventricle (especially in female rats) have been reported [30, 31]. Finally, MCT may induce oxidative stress, bringing high ROS production in the lungs and in RV and, as a consequence, producing cytotoxicity in the endothelial cells of pulmonary arteries [32].

As a result of 16-day supplementation with l-ARG and ND, separately or in combination, RV weight, RV/LV + S and RV/FBW ratios were found to have been restored, in both males and females, when compared to groups with PAH, with particular improvement noted in females. This effect was particularly visible when both compounds, l-ARG and ND were co-administered. This is consistent

### Discussion

Given that pulmonary arterial hypertension (PAH) is an extremely complex disease with a poor prognosis [25], further investigation in this clinical field is essential. This study is the first to investigate the impact of oral administration of l-arginine (l-ARG) and nicotinamide (ND), separately and in combination, on myocardial function and histopathological changes in pulmonary arteries during the development of PAH in a gender-dependent way. The major novel finding of this study is that the combination of the oral supplements l-ARG and ND prevented right ventricle enlargement and vascular changes in small pulmonary arteries induced by pulmonary hypertension, especially in females. Additionally, the contractility of the right ventricle and the reaction to a catecholamine (noradrenaline) was preserved and restored to the normal, control level.

We used a well-established model of PAH induced by monocrotaline (MCT) in rats [26]. MCT is a macrocyclic pyrrolizidine alkaloid obtained from seeds of a Crotalaria spectabilis plant. The exact mechanism of action of this compound is not known. After administration of MCT, a “monocrotaline syndrome” appears which is manifested by: acute necrotic inflammation of the pulmonary arteries and hypertrophy of the right ventricle [27]. In this study, MCT was administered at a dose of 60 mg/kg B.W., with an observational period of 23 days to allow full development of pathological changes in heart and pulmonary circulation. Higher doses may contribute to hepato-, cardio-, and nephrotoxicity and are associated with a higher mortality rate [27]. The use of this model was confirmed to be effective by Meyrick et al., who observed the remodeling of distal pulmonary arteries after 3 days and RV hypertrophy 7–14 days after MCT was administered [28]. Additionally, significant reductions of the FBW (especially in male rats) [29], increased levels of catecholamines and the enlargement of the right ventricle (especially in female rats) have been reported [30, 31]. Finally, MCT may induce oxidative stress, bringing high ROS production in the lungs and in RV and, as a consequence, producing cytotoxicity in the endothelial cells of pulmonary arteries [32].
Fig. 5  Histological analyses of male and female rat lung tissue. Effect of ARG and ND, administered separately and in combination, on PAH-induced changes in the thickness of the pulmonary arteries located in the area of the alveoli in male (♂) and female (♀) rats. Normal (a) pulmonary artery structures in Control, ARG, ND and ARG+ND male and female groups (a–d, respectively). Severely affected pulmonary arteries with PAH (black asterisk), thickening of the vessels walls (green asterisk) and narrowing of the vessels light (blue asterisk), inflammatory cell infiltration (arrowhead) in male and female (e) groups and congestion (red arrow) in male PAH (e) group. Normed pulmonary artery structures (b) in PAH+ARG male and female groups (f). Additional inflammatory cell infiltration (arrowhead) in PAH+ARG male group (f). Normed pulmonary artery structures (b) and inflammatory cell infiltration (arrowhead) in PAH+ND female (g) group and mild vasocongestion (plus) in PAH+ND male group (g). Normed (b) pulmonary arteries and inflammatory cell infiltration (arrowhead) in PAH+ARG+ND female group (h), and also vasocongestion (plus) and macrophages (black arrow) in PAH+ARG+ND male group (h); H&Ex400

with previously published data showing that the use of L-arginine significantly reduced PAH symptoms [33]. On the other hand, the protective effect of nicotinamide in males has been confirmed in studies of acute lung injury, where this compound, in a dose-dependent manner, weakened the action of a strong neutrophil activator [8]. We observed that a ND-rich diet had a better effect on females than males when considering RV weight alone and in relation to the final body weight, in comparison to groups with PAH. Alternatively, L-ARG alone and L-ARG combined with ND prevented vascular changes induced by pulmonary hypertension in more male than female rats. The mechanism for the observed protective effects of L-ARG and ND may be related to the abolition of oxidative stress, reduction of inflammation and, as a consequence, a decrease in iNOS activity [34]. It is worth noting that in the FPAH+ND group, the histological picture was definitely more unfavorable than the corresponding control group and even the PAH group (observed more extensive inflammation and edema). This correlates with visible RV hypertrophy in this female group. A possible explanation could be a non-specific interaction between ND and MCT, or this substance could be hepatically metabolized in a different way in female as compared to male groups treated with ND [35].

Another unexplained study result related to the reduced (non-significant) resting (basal) force of contraction ($F_c$) in males with pulmonary hypertension. The possible reason for this could be attributed to the effects of monocrotaline on the $\beta_1$-adrenergic receptor signaling pathway, subsequently
decreasing the production of cAMP content, as previously noted [36, 37]. Conversely, in the group of females with PAH, a significant increase of the resting force of contraction was observed. The cause of this gender discrepancy may be associated with the protective effects of estrogen in females, as well as the potential for males to experience a greater enlargement of the right ventricle during the development of PAH. This is consistent with previously published data on the strong cardioprotective effects of estrogen in different clinical situations [26, 38].

Our data clearly demonstrated that the addition of L-ARG and ND, separately or in combination, restored resting $F_c$ to the control values in both male and female rats with PAH.

L-Arginine as a precursor of NO, exerts a negligible inotropic effect on the myocardium, on vasorelaxation as well as inhibits platelet activity under standard conditions [14, 15]. However, PAH induces endothelial dysfunction, which leads to the limited synthesis of NO.

Nicotinamide, is a cytoprotective compound with anti-inflammatory properties, which can also modulate the SUR2A subunit of ATP-dependent potassium channels in cardiomyocytes [10, 39]. It may play an important role in cardioprotection and may improve myocardial efficiency by inhibiting poly (ADP-ribose) and preventing the inhibition of mitochondrial respiration whilst simultaneously maintaining the balance of ATP in cells [8]. In addition, nicotinamide...
has anti-inflammatory properties resulting from the inhibition of iNOS synthase and the ability to remove free radicals [34].

In this study, we also examined the adrenergic responsiveness of right ventricular muscle under different experimental settings, using noradrenaline (NA), as the agonist of α and β₁ adrenergic receptors. We observed the positive inotropic action of NA in all control and experimental groups, and observed a slight tendency of groups with PAH to have increased reaction to NA, which was restored to the control values by the addition of L-ARG, ND or L-ARG + ND. It is important to note that ND alone strongly increased responses to noradrenaline in the control female group, but decreased it in the group with pulmonary hypertension. Further research
is needed to clarify the mechanism of the above-mentioned phenomenon.

To conclude, our study clearly showed that combined administration of l-arginine and nicotinamide has protective effects on vascular remodeling and myocardium contractility in PAH in a gender-independent way. This is of clinical interest considering a fact that female patients predominate this condition (4:1) [35]. However, the effects of these diets in humans with PAH are still unknown. To find out the clinical efficacy of this supplementation in PAH, further studies are meaningful and necessary, hopefully, providing more options for the treatment of this serious disease.

Acknowledgements This work was supported by grant MN from the Medical University of Gdansk, Poland (Grant numbers 01-0003/08). Authors are grateful to Natalia Krzyzanik from Institute of Evidence-Based Practice, Bond University, Gold Coast, Australia, for style and grammar correction.

Author contributions IK and KSA prepared the study design and experimental protocols. KSA performed in vitro and in vivo experiments. ZJ performed histopathology examination of lung tissue. IK and KSA contributed to data analysis and writing the manuscript. All authors read and approved the final manuscript. All data were generated in-house.

Compliance with ethical standards

Conflict of interest The authors declare that there is no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208.
2. Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2011;115:176–88.
3. Haddad F, Spruit OA, Denuault A, Mercier O, Brunner D, et al. Right heart score for predicting outcome in idiopathic, familial, or drug- and toxin-associated pulmonary arterial hypertension. JACC Cardiovasc Imaging. 2015;8:627–38.
4. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511–9.
5. Ryan JJ, Huston J, Kuty S, Hatton ND, Bowman L, Tian L, et al. Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol. 2015;31:391–406.
6. Tofovic PS, Zhang X, Petrusveska G. Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen-deficient rats. Prilozi. 2009;30:25–44.
7. Ungerstedt JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131:48–52.
8. Lin C-C, Hsieh N-K, Liou HL, Chen HI. Nicotinamide mitigated the acute lung injury induced by phorbol myristate acetate in isolated rat’s lungs. J Biomed Sci. 2012;19:27.
9. Peralta-Leal A, Rodriguez-Vargas JM, Aguilar-Quesada R, Rodriguez MI, Linares JL, de Almodóvar MR, et al. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med. 2009;47:13–26.
10. Sukhodub A, Du Q, Jovanovic S, Jovanovic A. Nicotinamide-rich diet protects the heart against ischaemia–reperfusion in mice: a crucial role for cardiac SUR2A. PharmacoL Res. 2010;61:564–70.
11. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation. 1993;87:1475–81.
12. Wu G, Meiningier CJ, Knabe DA, Bazer FW, Rhoads JM. Arginine nutrition in development, health and disease. Curr Opin Clin Nutr Metab Care. 2000;3:59–66.
13. Solomonson LP, Flam BR, Pendleton LC, Goodwin BL, Eichler DC. The caveolar nitric oxide synthase/arginine regeneration system for NO production in endothelial cells. J Exp Biol. 2003;206:2083–7.
14. Sim JY. Nitric oxide and pulmonary hypertension. Korean J Anesthesiol. 2010;58:4–14.
15. Cotton JM, Kearney MT, Shah AM. Nitric oxide and myocardial function in heart failure: friend or foe? Heart. 2002;88:564–6.
16. Moura JR, Sass N, Guimarães SB, Vasconcelos PR, Mattar R, Kulya L Jr. Effects of l-arginine oral supplements in pregnant spontaneously hypertensive rats. Acta Cir Bras. 2006;21:192–6.
17. Melo SS, Arantes MR, Meirelles MS, Jardão AA Jr, Vannucci H. Lipid peroxidation in nicotinamide-deficient and nicotinamide-supplemented rats with streptozotocin-induced diabetes. Acta Diabetol. 2000;37:33–9.
18. Słomińska EM, Adamski P, Lipiński M, Święcickański J, Smoleński RT. Liquid chromatographic/mass spectrometric procedure for measurement of NAD catabolite in human and rat plasma and urine. Nucleosides Nucleotides Nucleic Acids. 2006;25:1245–9.
19. Malfatti CRM, da Silva LA, Pereira RA, Michel RG, Snak AL, dos Santos FS. Acute hypothalamic administration of l-arginine increases feed intake in rats. Rev Nutr. 2015;28:55–63.
20. Bhummer PM, Baughn JA, Sanders LP, Absher KR, O’Connor WN, et al. Surfactant disposition in rats with monocrotaline-induced pneumotoxicity. Toxicology. 1994;90:53–62.
21. Fulton RM, Hutchinson EC, Jones AM. Ventricular weight in cardiac hypertrophy. Br Heart J. 1952;14(3):413–20.
22. Bueno-Beti C, Sassi Y, Hajjar RJ, Hadri L. Pulmonary artery hypertension model in rats by monocrotaline administration. Methods Mol Biol. 2018;1816:233–41.
23. Meyrick B, Gamble W, Reid L. Development of crotalaria pulmonarhypertension: hemodynamic and structural study. Am J Physiol. 1980;239:H692–702.
24. Baybutt RC, Rosales C, Brady H, Molteni A. Dietary fish oil protects against lung and liver inflammation and fibrosis in monocrotaline treated rats. Toxicology. 2002;175:1–13.

25. Piacentini E, López-Aguilar J, García-Martín C, Villagrá A, Saenz-Valiente A, Murias G, et al. Effects of vascular flow and PEEP in a multiple hit model of lung injury in isolated perfused rabbit lungs. J Trauma. 2008;65:147–53.

26. Kocić I, Szczepańska R, Wapniarska I. Estrogen-induced relaxation of the rat tail artery is attenuated in rats with pulmonary hypertension. Pharmacol Rep. 2010;62:95–9.

27. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302:L363–9.

28. Meyrick B, Reid L. Development of pulmonary arterial changes in rats fed Crotalaria spectabilis. Am J Pathol. 1979;94:37–51.

29. Steffen BT, Lees SJ, Booth FW. Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. J Appl Physiol. 1985;2008(105):1950–8.

30. Leineweber K, Seyfarth T, Brodde O-E. Chamber-specific alterations of noradrenaline uptake (uptake1) in right ventricles of monocrotaline-treated rats. Br J Pharmacol. 2000;131:1438–44.

31. Hemnes AR, Champion HC. Right heart function and haemodynamics in pulmonary hypertension. Int J Clin Pract Suppl. 2008;160:11–9.

32. Mam V, Tanbe AF, Vitali SH, Arons E, Christon HA, Khalil RA. Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 2010;332:455–62.

33. YanYun P, Wang S, Yang J, Chen B, Sun Z, Ye L, et al. Interruption of CD40 pathway improves efficacy of transplanted endothelial progenitor cells in monocrotaline induced pulmonary arterial hypertension. Cell Physiol Biochem. 2015;36:683–96.

34. Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43:1691–7.

35. Mair KM, Johansen AK, Wright AF, Wallace E, MacLean MR. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Br J Pharmacol. 2014;171:567–79.

36. Leineweber K, Seyfarth T, Abraham G, Gerbershagen HP, Heinroth-Hoffmann I, Pönicker K, et al. Cardiac beta-adrenoceptor changes in monocrotaline-treated rats: differences between membrane preparations from whole ventricles and isolated ventricular cardiomyocytes. J Cardiovasc Pharmacol. 2003;41:333–42.

37. Brown L, Miller J, Dagger A, Sernia C. Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. J Cardiovasc Pharmacol. 1998;31:108–15.

38. Wolbrette D, Naccarelli G, Curtis A, Lehmann M, Kadiash A. Gender differences in arrhythmias. Clin Cardiol. 2002;25:49–56.

39. Crawford RM, Jovanović S, Budas GR, Davies AM, Lad H, Wenger RH, et al. Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channel. J Biol Chem. 2003;278:31444–55.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.